Updates in Cardiovascular Medicine

Slides:

Advertisements

Similar presentations

FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Advertisements

NICE –CG 181 Continuum of CVD Risk and its treatment

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Louise Bowman & Martin Landray on.

Reduction in Total Cardiovascular Events with the PCSK9 Inhibitor Evolocumab in Patients with Cardiovascular Disease in the FOURIER Trial Sabina A. Murphy,

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.

The Latest Lipid Guidelines:

PCSK9 Inhibitors and Cardiovascular Outcomes Trials

Diabetic Dyslipidemia in Practice

Updates and Perspectives in Diabetic Dyslipidemia

What is the likely mechanism by which HDL-C reduces coronary heart disease?

PCSK9 Inhibitors Post-CVOTs

Statin Selection in the Elderly

Current Dyslipidemia Management Guidelines Residual Risk.

An Endocrinology Clinic in Dyslipidemia

Diabetes and Dyslipidemia

A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective

Cardiovascular Disease Risk Reduction Advances in Dyslipidemia

Cholesteryl Ester Transfer Protein Inhibitors

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Select Topics in Cardiovascular Medicine

American Heart Association Scientific Sessions

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Statins and the Elderly Patient

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Beyond Statin Therapy.

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Statin Class in Session

An Update on PCSK9 Inhibitors

Evaluating LDL-C Recommendations

New Pathways in Lipid Care

62-year-old Man With Unstable Angina

Statin Class in Session

CV Risk Doesn't End in the Cath Lab

PCSK9 Inhibitors and Cardiovascular Outcomes

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

Improving Appropriate Access to PCSK9 Inhibitors

EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

New LDL-C Lipid Targets

A PCP's Guide to Dyslipidemia

Radical New Concepts in Lipid Management

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

CV Risk Doesn't End in the Cath Lab

Clinicians' Corner in Dyslipidemia

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

Latest Lipid Guidelines in Perspective

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Reducing Risk for CV Outcomes

Potential mechanisms whereby statins may reduce the risk of stroke

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

DECLARE-TIMI 58.

New Lipid-Lowering Guidelines

Lipid Updates From Spring 2019

New Lipid-Lowering Therapies

An Update on PCSK9 Inhibitors

Updates on Dyslipidemia

Lipids, the Heart, and the Kidney

in diabetic patients with mixed dyslipidemia

LDL-c reductions below 1

PCSK9 Inhibitors and Real-World Evidence

Shared-Decision Making in Dyslipidemia

Presentation transcript:

Updates in Cardiovascular Medicine

Update on Nonstatin Therapies in LDL-C lowering

PROVE-IT Intensive vs Standard Statin Therapy

IMPROVE-IT Ezetimibe Added to Statin Therapy

FOURIER PCSK9 Inhibitor Added to Statin Therapy

Reverse Cholesterol Transport and CETP Inhibition

Lipid Effects of CETP Inhibitors

CETP Inhibitor Clinical Trials

REVEAL HPS3 TIMI-55

REVEAL Trial Design

REVEAL Primary Outcome

Additional Clinical Outcomes of Anacetrapib

Effects of Anacetrapib on Coronary Death or MI

Potential Clinical Implications of CETP inhibitors

Summary of CETP Inhibitors

Potential Clinical Implications of CETP Inhibitors

Abbreviations

Abbreviations (cont)

Abbreviations (cont)